Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Published Online
on June 10, 2004

Stroke. 2004
Published online before print June 10, 2004, doi: 10.1161/01.STR.0000132570.24618.78
A more recent version of this article appeared on August 1, 2004
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
35/8/1790    most recent
01.STR.0000132570.24618.78v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cantu, C.
Right arrow Articles by Barinagarrementeria, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cantu, C.
Right arrow Articles by Barinagarrementeria, F.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*CYANOCOBALAMIN
*FOLIC ACID
Related Collections
Right arrow Clinical genetics
Right arrow Thrombophilia
Right arrow Thrombosis risk factors
Right arrow Cerebral Venous Thrombosis

Submitted on December 3, 2003
Revised on April 16, 2004
Accepted on April 21, 2004

Hyperhomocysteinemia, Low Folate and Vitamin B12 Concentrations, and Methylene Tetrahydrofolate Reductase Mutation in Cerebral Venous Thrombosis

Carlos Cantu MD, MSc*; Elisa Alonso MD; Aurelio Jara BSc; Leticia Martínez BSc; Camilo Ríos Ch, PhD; María de los Angeles Fernández BSc; Irma Garcia BSc; and Fernando Barinagarrementeria MD

From the Stroke Clinic (C.C., F.B.) and the Departments of Genetics (E.A., A.J., L.M.), Neurochemistry (C.R.), and Radioimmunoassay (M.d.l.A.F., I.G.), Instituto Nacional de Neurología y Neurocirugía "Manuel Velasco Suárez," Mexico C.C. is now appointed at the Stroke Clinic, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City. F.B. has moved to Hospital Angeles, Querétaro, Mexico.

* To whom correspondence should be addressed. E-mail: carloscantu_brito{at}hotmail.com.

Background--Elevated plasma levels of homocysteine are associated with an increased risk of deep-vein thrombosis. Through a case-control study, we examined the potential association among homocysteine, folate and vitamin B12 levels, and the common C677->T mutation in the methylene tetrahydrofolate reductase (MTHFR) gene in patients with cerebral venous thrombosis (CVT).

Methods--Forty-five patients with CVT and 90 control subjects were studied. Plasma levels of homocysteine (fasting and after methionine load), folate, and vitamin B12 were measured. Genotyping of the MTHFR gene was also performed. The estimated risk of CVT associated with hyperhomocysteinemia, low vitamin levels, and MTHFR mutation were expressed as odds ratio (OR) and its 95% CI (crude and after adjusting by other independent variables).

Results--The adjusted OR for CVT associated with high (>90th percentile) fasting levels of homocysteine was 4.6 (1.6 to 12.8). The association between low plasma folate values (<10th percentile) and presence of CVT was 3.5 (1.2 to 10.0) after adjustment for confounding factors. There was a higher frequency of MTHFR mutation in patients with CVT (22% versus 10%), but it was not statistically significant (P=0.098). Patients with MTHFR mutation and low folate levels presented the highest homocysteine levels.

Conclusions--High plasma concentrations of homocysteine and low plasma folate levels were associated with an increased risk of CVT in this population in which low socioeconomic conditions and deficient nutritional status may contribute to its relatively high incidence.


Key words: cerebral thrombosis • sinus thrombosis • risk factors • coagulation • homocysteine




This article has been cited by other articles:


Home page
CLIN APPL THROMB HEMOSTHome page
V. Ducros, C. Barro, J. Yver, G. Pernod, B. Polack, P. Carpentier, M.-D. Desruet, and J.-L. Bosson
Should Plasma Homocysteine Be Used as a Biomarker of Venous Thromboembolism? A Case--Control Study
Clinical and Applied Thrombosis/Hemostasis, October 1, 2009; 15(5): 517 - 522.
[Abstract] [PDF]


Home page
StrokeHome page
E. S. Roach, M. R. Golomb, R. Adams, J. Biller, S. Daniels, G. deVeber, D. Ferriero, B. V. Jones, F. J. Kirkham, R. M. Scott, et al.
Management of Stroke in Infants and Children: A Scientific Statement From a Special Writing Group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the Young
Stroke, September 1, 2008; 39(9): 2644 - 2691.
[Abstract] [Full Text] [PDF]


Home page
CMAJHome page
C. L. Wong MD, H. G.C. Van Spall MD, K. A. Hassan MB, J. Coret-Simon MD, D. J. Sahlas MD, and S. L. Shumak MD
A young man with deep vein thrombosis, hyperhomocysteinemia and cobalamin deficiency
Can. Med. Assoc. J., January 29, 2008; 178(3): 279 - 281.
[Full Text] [PDF]


Home page
BloodHome page
F. Dentali, M. Crowther, and W. Ageno
Thrombophilic abnormalities, oral contraceptives, and risk of cerebral vein thrombosis: a meta-analysis
Blood, April 1, 2006; 107(7): 2766 - 2773.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
J. Stam
Thrombosis of the Cerebral Veins and Sinuses
N. Engl. J. Med., April 28, 2005; 352(17): 1791 - 1798.
[Full Text] [PDF]